Racial disparity in psychotropic medications prescribed for youths with medicaid insurance in Maryland

Julie Magno Zito, Daniel J. Safer, Susan DosReis, Mark A Riddle

Research output: Contribution to journalArticle

Abstract

Design: A retrospective analysis was conducted using state Medicaid prescription drug reimbursement claims for youths aged 5 through 14 years according to the race of the recipients of psychotropic and medical drugs. Method: A person-based data set was created from Medicaid administrative data for fiscal year 1991 from the state of Maryland to yield the following: (1) estimates of prevalence of prescription recipients per 100 eligible enrollees; (2) relative prescription use ratios according to race (African- American versus Caucasian); and (3) the interrelation of race and geographic region on prescription prevalence. Results: Five major findings were observed: (1) African-American youths with Medicaid insurance aged 5 through 14 were less than half (39% to 52%) as likely to have been prescribed psychotropic medications as Caucasian youths with Medicaid insurance; (2) the relative difference for nonpsychotropic medication classes was much less pronounced: African-American youths were prescribed nonpsychotropic medications at a rate 60% to 87% of the Caucasian youths' rate; (3) the stimulants (essentially methylphenidate) had the most disparate African- American/Caucasian ratio (1:2.5); (4) the racial disparity for psychotropics was not altered by partial (noncontinuous enrollment) eligibility status; and (5) although geographic variation reduced the racial disparity, the substantial racial difference (1:2.0) remained. Conclusion: Compared with Caucasians, African-American youths aged 5 through 14 with Medicaid insurance coverage showed a distinctly lower rate of treatment with psychopharmacological agents.

Original languageEnglish (US)
Pages (from-to)179-184
Number of pages6
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume37
Issue number2
StatePublished - Feb 1998
Externally publishedYes

Fingerprint

Medicaid
Insurance
African Americans
Prescriptions
Methylphenidate
Insurance Coverage
Prescription Drugs
Psychotropic Drugs

Keywords

  • Child and adolescent pharmacotherapy
  • Medicaid
  • Pharmacoepidemiology
  • Psychotropic drug utilization
  • Race

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

@article{a86c07b96e7d46b493ba9f25475c0b5a,
title = "Racial disparity in psychotropic medications prescribed for youths with medicaid insurance in Maryland",
abstract = "Design: A retrospective analysis was conducted using state Medicaid prescription drug reimbursement claims for youths aged 5 through 14 years according to the race of the recipients of psychotropic and medical drugs. Method: A person-based data set was created from Medicaid administrative data for fiscal year 1991 from the state of Maryland to yield the following: (1) estimates of prevalence of prescription recipients per 100 eligible enrollees; (2) relative prescription use ratios according to race (African- American versus Caucasian); and (3) the interrelation of race and geographic region on prescription prevalence. Results: Five major findings were observed: (1) African-American youths with Medicaid insurance aged 5 through 14 were less than half (39{\%} to 52{\%}) as likely to have been prescribed psychotropic medications as Caucasian youths with Medicaid insurance; (2) the relative difference for nonpsychotropic medication classes was much less pronounced: African-American youths were prescribed nonpsychotropic medications at a rate 60{\%} to 87{\%} of the Caucasian youths' rate; (3) the stimulants (essentially methylphenidate) had the most disparate African- American/Caucasian ratio (1:2.5); (4) the racial disparity for psychotropics was not altered by partial (noncontinuous enrollment) eligibility status; and (5) although geographic variation reduced the racial disparity, the substantial racial difference (1:2.0) remained. Conclusion: Compared with Caucasians, African-American youths aged 5 through 14 with Medicaid insurance coverage showed a distinctly lower rate of treatment with psychopharmacological agents.",
keywords = "Child and adolescent pharmacotherapy, Medicaid, Pharmacoepidemiology, Psychotropic drug utilization, Race",
author = "Zito, {Julie Magno} and Safer, {Daniel J.} and Susan DosReis and Riddle, {Mark A}",
year = "1998",
month = "2",
language = "English (US)",
volume = "37",
pages = "179--184",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Racial disparity in psychotropic medications prescribed for youths with medicaid insurance in Maryland

AU - Zito, Julie Magno

AU - Safer, Daniel J.

AU - DosReis, Susan

AU - Riddle, Mark A

PY - 1998/2

Y1 - 1998/2

N2 - Design: A retrospective analysis was conducted using state Medicaid prescription drug reimbursement claims for youths aged 5 through 14 years according to the race of the recipients of psychotropic and medical drugs. Method: A person-based data set was created from Medicaid administrative data for fiscal year 1991 from the state of Maryland to yield the following: (1) estimates of prevalence of prescription recipients per 100 eligible enrollees; (2) relative prescription use ratios according to race (African- American versus Caucasian); and (3) the interrelation of race and geographic region on prescription prevalence. Results: Five major findings were observed: (1) African-American youths with Medicaid insurance aged 5 through 14 were less than half (39% to 52%) as likely to have been prescribed psychotropic medications as Caucasian youths with Medicaid insurance; (2) the relative difference for nonpsychotropic medication classes was much less pronounced: African-American youths were prescribed nonpsychotropic medications at a rate 60% to 87% of the Caucasian youths' rate; (3) the stimulants (essentially methylphenidate) had the most disparate African- American/Caucasian ratio (1:2.5); (4) the racial disparity for psychotropics was not altered by partial (noncontinuous enrollment) eligibility status; and (5) although geographic variation reduced the racial disparity, the substantial racial difference (1:2.0) remained. Conclusion: Compared with Caucasians, African-American youths aged 5 through 14 with Medicaid insurance coverage showed a distinctly lower rate of treatment with psychopharmacological agents.

AB - Design: A retrospective analysis was conducted using state Medicaid prescription drug reimbursement claims for youths aged 5 through 14 years according to the race of the recipients of psychotropic and medical drugs. Method: A person-based data set was created from Medicaid administrative data for fiscal year 1991 from the state of Maryland to yield the following: (1) estimates of prevalence of prescription recipients per 100 eligible enrollees; (2) relative prescription use ratios according to race (African- American versus Caucasian); and (3) the interrelation of race and geographic region on prescription prevalence. Results: Five major findings were observed: (1) African-American youths with Medicaid insurance aged 5 through 14 were less than half (39% to 52%) as likely to have been prescribed psychotropic medications as Caucasian youths with Medicaid insurance; (2) the relative difference for nonpsychotropic medication classes was much less pronounced: African-American youths were prescribed nonpsychotropic medications at a rate 60% to 87% of the Caucasian youths' rate; (3) the stimulants (essentially methylphenidate) had the most disparate African- American/Caucasian ratio (1:2.5); (4) the racial disparity for psychotropics was not altered by partial (noncontinuous enrollment) eligibility status; and (5) although geographic variation reduced the racial disparity, the substantial racial difference (1:2.0) remained. Conclusion: Compared with Caucasians, African-American youths aged 5 through 14 with Medicaid insurance coverage showed a distinctly lower rate of treatment with psychopharmacological agents.

KW - Child and adolescent pharmacotherapy

KW - Medicaid

KW - Pharmacoepidemiology

KW - Psychotropic drug utilization

KW - Race

UR - http://www.scopus.com/inward/record.url?scp=0031935455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031935455&partnerID=8YFLogxK

M3 - Article

C2 - 9473914

AN - SCOPUS:0031935455

VL - 37

SP - 179

EP - 184

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 2

ER -